{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:23:48Z","timestamp":1792002228172,"version":"4.4.0"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Breast Cancer\ufffd(Auckl)"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Tumour lysis syndrome (TLS) is a medical emergency occurring when large numbers of cancer cells rapidly undergo cell death. The resultant metabolic abnormalities results in significant morbidity and mortality. Tumour lysis syndrome most commonly occurs in 5% of haematological malignancies and is less commonly described in solid organ cancers. In breast cancer, TLS has been reported to occur both spontaneously and as a result of cancer chemotherapy, targeted therapy, or radiotherapy. However, only 1 TLS case in a breast cancer patient has been reported as a consequence of aromatase inhibitor letrozole. With the increased recent use of CDK4\/6 inhibitors, 2 cases of hyperuricaemia in patients with breast cancer treated with palbociclib\/letrozole combination treatment have also been reported. We present the second case of letrozole-induced TLS in a 74-year-old woman with occult breast adenocarcinoma. Despite treatment with recombinant urate oxidase and intravenous fluids, the patient deteriorated and was discharged with hospice care. Although rare, this life-threatening condition should be considered in an acutely unwell patient commencing treatment for solid malignant tumours.<\/jats:p>","DOI":"10.1177\/11782234211006677","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T23:51:11Z","timestamp":1618271471000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Tumour Lysis Syndrome in Occult Breast Cancer Treated With Letrozole \u2013 A Rare Occurrence. A Case Report and Review"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7398-4333","authenticated-orcid":false,"given":"George E","family":"Watkinson","sequence":"first","affiliation":[{"name":"General Medical Department, Rotorua Hospital, Rotorua, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth","family":"Hari Dass","sequence":"additional","affiliation":[{"name":"Oncology Department, Rotorua Hospital, Rotorua, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03330280059032"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000054661."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08143.x."},{"key":"e_1_3_2_6_2","first-page":"1529","article-title":"Gemcitabine-induced tumour lysis syndrome caused by recurrent breast cancer in a patient without haemodialysis","volume":"40","author":"Kawaguchi Ushio A","year":"2013","unstructured":"Kawaguchi Ushio A, Hattori M, Kohno N, Kaise H, Iwata H. Gemcitabine-induced tumour lysis syndrome caused by recurrent breast cancer in a patient without haemodialysis. Gan To Kagaku Ryoho. 2013;40:1529-1532.","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_3_2_7_2","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020726s014lbl.pdf. Accessed January 3 2020."},{"key":"e_1_3_2_8_2","first-page":"112","article-title":"Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report","volume":"16","author":"Zigrossi P","year":"2001","unstructured":"Zigrossi P, Brustia M, Bobbio F, Campanini M. Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report. Ann Ital Med Int. 2001;16:112-117.","journal-title":"Ann Ital Med Int"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2014.5389"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198607243150417."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199502000-00015."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Idrees M Fatima S Bravin E. Spontaneous tumor lysis syndrome: a rare presentation in breast cancer. J Med Case. 2019;10:24-26. https:\/\/journalmc.org\/index.php\/JMC\/article\/view\/3237\/2532","DOI":"10.14740\/jmc3237"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6186."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008347226743."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327481602300110."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2005.n.012"},{"key":"e_1_3_2_17_2","article-title":"Tumor lysis syndrome: a rare complication of chemotherapy for metastatic breast cancer","volume":"11","author":"Aslam HM","year":"2019","unstructured":"Aslam HM, Zhi C, Wallach SL. Tumor lysis syndrome: a rare complication of chemotherapy for metastatic breast cancer. Cureus. 2019;11:e4024. doi:10.7759\/cureus.4024.","journal-title":"Cureus"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-016-0969-5."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-013-0448-4."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870815)60."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2014.07.039."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703101221."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D164."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199412000-00010"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2006.00326.x."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_504_17."}],"container-title":["Breast Cancer: Basic and Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11782234211006677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11782234211006677","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11782234211006677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:56:30Z","timestamp":1777380990000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11782234211006677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":25,"alternative-id":["10.1177\/11782234211006677"],"URL":"https:\/\/doi.org\/10.1177\/11782234211006677","relation":{},"ISSN":["1178-2234","1178-2234"],"issn-type":[{"value":"1178-2234","type":"print"},{"value":"1178-2234","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"11782234211006677"}}